Evotec SE (NASDAQ:EVO - Get Free Report) shares saw an uptick in trading volume on Friday . 571,431 shares traded hands during trading, an increase of 348% from the previous session's volume of 127,496 shares.The stock last traded at $5.51 and had previously closed at $5.10.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft lowered Evotec from a "hold" rating to a "sell" rating in a research report on Thursday, August 8th. Jefferies Financial Group lowered Evotec from a "buy" rating to a "hold" rating and lowered their target price for the company from $8.70 to $3.80 in a research note on Monday, October 7th. Morgan Stanley downgraded shares of Evotec from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. Finally, HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of Evotec in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $5.93.
Check Out Our Latest Analysis on EVO
Evotec Trading Up 6.7 %
The firm has a 50 day moving average price of $3.66 and a 200-day moving average price of $4.20. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.
Hedge Funds Weigh In On Evotec
Several large investors have recently bought and sold shares of the business. Novo Holdings A S bought a new position in Evotec during the second quarter worth about $71,183,000. Wellington Management Group LLP boosted its stake in Evotec by 29.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after acquiring an additional 602,858 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in Evotec during the third quarter valued at approximately $512,000. DCF Advisers LLC grew its holdings in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after purchasing an additional 67,156 shares during the period. Finally, Clear Harbor Asset Management LLC bought a new stake in Evotec in the third quarter valued at approximately $104,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
